These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8807046)

  • 21. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628.
    Anderson R; Jooné GK
    Chemotherapy; 1993; 39(6):424-31. PubMed ID: 8222871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.
    Guillemin I; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2084-8. PubMed ID: 9687411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T; Zhao X; Drlica K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Roadblock-and-Kill Mechanism of Action Model for the DNA-Targeting Antibiotic Ciprofloxacin.
    Ojkic N; Lilja E; Direito S; Dawson A; Allen RJ; Waclaw B
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
    Yokota S; Sato T; Okubo T; Ohkoshi Y; Okabayashi T; Kuwahara O; Tamura Y; Fujii N
    Chemotherapy; 2012; 58(1):52-9. PubMed ID: 22343392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys.
    Giraud E; Leroy-Sétrin S; Flaujac G; Cloeckaert A; Dho-Moulin M; Chaslus-Dancla E
    J Antimicrob Chemother; 2001 Mar; 47(3):341-3. PubMed ID: 11222567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of ciprofloxacin and lomefloxacinin fluoroquinolone-resistant strains of Escherichia coli.
    Xia P; Feng P; Zhong L; Lu X; Lei B
    Chin Med J (Engl); 2002 Jan; 115(1):31-5. PubMed ID: 11930654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro activity of fluoroquinolones and oral beta lactam antibiotics against clinical isolates of Escherichia coli].
    Gómez-Martínez J; Marco F; Mensa J; Espasa M; Martínez JA; Jiménez de Anta MT
    Rev Esp Quimioter; 1999 Mar; 12(1):54-7. PubMed ID: 10209063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin.
    Govendir M; Hansen T; Kimble B; Norris JM; Baral RM; Wigney DI; Gottlieb S; Malik R
    Vet Microbiol; 2011 Jan; 147(1-2):113-8. PubMed ID: 20619975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of the AcrAB-TolC efflux pump to high-level fluoroquinolone resistance in Escherichia coli isolated from dogs and humans.
    Sato T; Yokota S; Okubo T; Ishihara K; Ueno H; Muramatsu Y; Fujii N; Tamura Y
    J Vet Med Sci; 2013 May; 75(4):407-14. PubMed ID: 23149545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.